Printer Friendly

Printed from http://www.researchandmarkets.com/reports/2114471

Uterine Cancer - Pipeline Review, H1 2012

Description:

Uterine Cancer – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Uterine Cancer - Pipeline Review, H1 2012', provides an overview of the Uterine Cancer therapeutic pipeline. This report provides information on the therapeutic development for Uterine Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uterine Cancer. 'Uterine Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Uterine Cancer.
- A review of the Uterine Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Uterine Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Uterine Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Uterine Cancer pipeline depth and focus of Uterine Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Uterine Cancer Therapeutic Products under Development, Key Players in Uterine Cancer Therapeutics, Uterine Cancer Pipeline Overview, Uterine Cancer Pipeline, Uterine Cancer Pipeline Assessment

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Uterine Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Uterine Cancer
Uterine Cancer Therapeutics under Development by Companies
Uterine Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Uterine Cancer Therapeutics – Products under Development by Companies
Uterine Cancer Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Uterine Cancer Therapeutics Development
Bristol-Myers Squibb Company
Helix BioPharma Corp.
Sanofi-Aventis
AstraZeneca PLC
GlaxoSmithKline plc
Genentech, Inc.
Inovio Biomedical Corporation
Daiichi Sankyo Company, Ltd
Merck & Co., Inc.
YM BioSciences Inc.
MediGene AG
Novartis AG
Eisai Co., Ltd.
Pfizer Inc.
Taiho Pharmaceutical Co., Ltd.
Zeria Pharmaceutical Co Ltd
CEL-SCI Corporation
Advaxis, Inc.
3SBio Inc.
Neogenix Oncology Corporation
EntreMed, Inc.
AEterna Zentaris Inc.
Critical Outcome Technologies Inc.
Dendreon Corporation
Transgene SA
RXi Pharmaceuticals Corporation
Antigen Express, Inc.
Affitech A/S
Nutri Pharma ASA
Acceleron Pharma, Inc.
InterMed Discovery GmbH
ApoImmune, Inc.
PDS Biotechnology Corporation
Endocyte, Inc.
Esperance Pharmaceuticals, Inc.
BT PHARMA
PharmaMar, S.A.
Genetic Immunity, LLC
Advanced Cancer Therapeutics
Eurofarma
ISA Pharmaceuticals B.V.
Coridon Pty Ltd
Uterine Cancer – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Cisplatin + Radiation Therapyy - Drug Profile
Sotatercept - Drug Profile
Z-100 - Drug Profile
V503 - Drug Profile
Paclitaxel + Cisplatin - Drug Profile
Trabectedin - Drug Profile
Ixempra - Drug Profile
Cisplatin + Navelbine - Drug Profile
Tirapazamine + Cisplatin + Radiation Therapy - Drug Profile
Gemcitabine + Cisplatin - Drug Profile
Pegfilgrastim + Docetaxel + Gemcitabine - Drug Profile
Bevacizumab + Filgrastim + Docetaxel + Gemcitabine - Drug Profile
Gemcitabine + Cisplatin - Drug Profile
Carboplatin + Cisplatin + Paclitaxel + Radiation Therapy - Drug Profile
Medroxyprogesterone Acetate - Drug Profile
Paclitaxel + Carboplatin - Drug Profile
Gemcitabine + Docetaxel + Filgrastim + Pegfilgrastim - Drug Profile
Cisplatin + Paclitaxel - Drug Profile
Carboplatin + Paclitaxel + Cisplatin + Radiation Therapy - Drug Profile
Cisplatin + Paclitaxel - Drug Profile
Ifosfamide + Paclitaxel - Drug Profile
Paclitaxel + Carboplatin + Brachytherapy - Drug Profile
S-1 + Cisplatin - Drug Profile
Epoetin alfa + Cisplatin + Brachytherapy + Radiation therapy - Drug Profile
Cisplatin + Paclitaxel + Radiation Therapy - Drug Profile
Gardasil - Drug Profile
Topotecan + Paclitaxel - Drug Profile
Bevacizumab + Paclitaxel + Topotecan - Drug Profile
Topotecan + Cisplatin - Drug Profile
Bevacizumab + Cisplatin + Paclitaxel - Drug Profile
Carboplatin + Cisplatin + Paclitaxel + Radiation Therapy - Drug Profile
Cisplatin + Radiation Therapy - Drug Profile
Paclitaxel + Doxorubicin + Cisplatin + Filgrastim - Drug Profile
Letrozole - Drug Profile
Cisplatin + Radiation Therapy - Drug Profile
Paclitaxel + Cisplatin - Drug Profile
Paclitaxel + Topotecan - Drug Profile
Paclitaxel + Topotecan - Drug Profile
Gendicine + Radiation Therapy - Drug Profile
Topotecan + Cisplatin - Drug Profile
Doxorubicin + Cisplatin - Drug Profile
Docetaxel + Cisplatin - Drug Profile
Cisplatin + Vincristine - Drug Profile
Filgrastim + Cisplatin + Doxorubicin Hydrochloride + Megestrol Acetate + Paclitaxel + Tamoxifen Citrate - Drug Profile
Filgrastim + Cisplatin + Doxorubicin Hydrochloride + Megestrol Acetate + Paclitaxel + Tamoxifen Citrate - Drug Profile
Cisplatin + Hyperthermia Therapy + Radiation Therapy - Drug Profile
Cyclophosphamide - Drug Profile
Carboplatin + Methotrexate + Vinblastine - Drug Profile
Platinex + Radiation Therapy - Drug Profile
Fluorouracil + Radiation Therapy - Drug Profile
Gemcitabine + Cisplatin - Drug Profile
Cisplatin + Gemcitabine - Drug Profile
Paclitaxel + Cispaltin + Radiotherapy - Drug Profile
Cisplatin + Brachytherapy + Radiation Therapy - Drug Profile
Uracil-Tegafur + Radiation Therapy - Drug Profile
Cisplatin + Radiation Therapy - Drug Profile
Carboplatin + Paclitaxel - Drug Profile
Cisplatin + Vinorelbine + Nimotuzumab - Drug Profile
S-1 - Drug Profile
Uterine Cancer Therapeutics – Drug Profile Updates
Uterine Cancer Therapeutics – Discontinued Products
Uterine Cancer Therapeutics - Dormant Products
Uterine Cancer – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Uterine Cancer, H1 2012
Products under Development for Uterine Cancer – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Bristol-Myers Squibb Company, H1 2012
Helix BioPharma Corp., H1 2012
Sanofi-Aventis, H1 2012
AstraZeneca PLC, H1 2012
GlaxoSmithKline plc, H1 2012
Genentech, Inc., H1 2012
Inovio Biomedical Corporation, H1 2012
Daiichi Sankyo Company, Ltd, H1 2012
Merck & Co., Inc., H1 2012
YM BioSciences Inc., H1 2012
MediGene AG, H1 2012
Novartis AG, H1 2012
Eisai Co., Ltd., H1 2012
Pfizer Inc., H1 2012
Taiho Pharmaceutical Co., Ltd., H1 2012
Zeria Pharmaceutical Co Ltd, H1 2012
CEL-SCI Corporation, H1 2012
Advaxis, Inc., H1 2012
3SBio Inc., H1 2012
Neogenix Oncology Corporation, H1 2012
EntreMed, Inc., H1 2012
AEterna Zentaris Inc., H1 2012
Critical Outcome Technologies Inc., H1 2012
Dendreon Corporation, H1 2012
Transgene SA, H1 2012
RXi Pharmaceuticals Corporation, H1 2012
Antigen Express, Inc., H1 2012
Affitech A/S, H1 2012
Nutri Pharma ASA, H1 2012
Acceleron Pharma, Inc., H1 2012
InterMed Discovery GmbH, H1 2012
ApoImmune, Inc., H1 2012
PDS Biotechnology Corporation, H1 2012
Endocyte, Inc., H1 2012
Esperance Pharmaceuticals, Inc., H1 2012
BT PHARMA, H1 2012
PharmaMar, S.A., H1 2012
Genetic Immunity, LLC, H1 2012
Advanced Cancer Therapeutics, H1 2012
Eurofarma, H1 2012
ISA Pharmaceuticals B.V., H1 2012
Coridon Pty Ltd, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Uterine Cancer Therapeutics – Drug Profile Updates
Uterine Cancer Therapeutics – Discontinued Products
Uterine Cancer Therapeutics – Dormant Products
Uterine Cancer Therapeutics – Dormant Products (Contd..1)
Uterine Cancer Therapeutics – Dormant Products (Contd..2)
Uterine Cancer Therapeutics – Dormant Products (Contd..3)
Uterine Cancer Therapeutics – Dormant Products (Contd..4)
Uterine Cancer Therapeutics – Dormant Products (Contd..5)
Uterine Cancer Therapeutics – Dormant Products (Contd..6)
Uterine Cancer Therapeutics – Dormant Products (Contd..7)
Uterine Cancer Therapeutics – Dormant Products (Contd..8)
Uterine Cancer Therapeutics – Dormant Products (Contd..9)
Uterine Cancer Therapeutics – Dormant Products (Contd..10)
Uterine Cancer Therapeutics – Dormant Products (Contd..11)
Uterine Cancer Therapeutics – Dormant Products (Contd..12)
Uterine Cancer Therapeutics – Dormant Products (Contd..13)
Uterine Cancer Therapeutics – Dormant Products (Contd..14)
Uterine Cancer Therapeutics – Dormant Products (Contd..15)
Uterine Cancer Therapeutics – Dormant Products (Contd..16)

List of Figures
Number of Products under Development for Uterine Cancer, H1 2012
Products under Development for Uterine Cancer – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2

Printed Thursday, May 23, 2013
5:29:54 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Uterine Cancer - Pipeline Review, H1 2012

Web Address

http://www.researchandmarkets.com/reports/2114471

Office Code

OC8DIQSOLTWQTX

Report Formats

Please enter the quantity of the report format you require.

Format	Quantity	Price
Electronic (PDF) - Single User		EURO€ 384.00
Electronic (PDF) - Site License		EURO€ 769.00
Electronic (PDF) - Enterprisewide		EURO€ 1,153.00

Contact information

Please enter all the information below in block capitals.

                Title:
            
                    Mr
                    
                    Mrs
                    
                    Dr
                    
                    Miss
                    
                    Ms
                    
                    Prof
                    
                First Name:
            
                Last Name:
                
                Email Address:
            
                Job Title:
            
                Organisation:
            
                Address:
            
                City:
            
                Postal / Zip Code:	
            
                Country:	
            
                Phone Number:	
            
                Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2

Printed Thursday, May 23, 2013
5:29:54 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:

Cardholder's Signature:

Expiry Date:

Card Number:

CVV Security Code:

Issue date:

(Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:

Account Number:

83313083

Sort Code:

98-53-30

Swift Code:

ULSBIE2D

IBAN Number:

IE78ULSB98533083313083

Bank Address:

Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Printer Friendly

Uterine Cancer - Pipeline Review, H1 2012

Fax order form

Order information

Product name

Web Address

Office Code

Report Formats

Contact information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Payment information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)